Development of Measures to Screen for Financial Hardship in Alzheimer's Disease and Dementia
Fred Hutchinson Cancer Center · with National Institute on Aging (NIA), Johns Hopkins University · NCT06922188
Opens the official ClinicalTrials.gov record, with the study team’s contacts. Bored Studies doesn’t enroll anyone.
Key facts
- Compensation
- Not posted. Ask the study team before screening.
- Who can join
- Ages 18+ · All sexes
- Healthy volunteers
- Accepted
- Study type
- Observational
- Target enrollment
- 2460
- US sites recruiting
- 1
- Study start
- March 31, 2025
- Record last updated
- August 19, 2026
Status re-checked against ClinicalTrials.gov within the last 12 hours.
What the study is about
Alzheimer's Disease and related dementias (AD/ADRD) are common and debilitating conditions. Financial hardship, a multidimensional construct of financial strain, financial stress and asset depletion, is common in AD/ADRD due to exorbitant out-of-pocket spending such as for long-term care, lower work productivity and income for their caregivers that can last for decades after disease onset, and difficulty deciding between nursing home care or home-based care while negotiating insurance coverage. People from historically marginalized groups can experience a double disparity with fewer financial resources to manage AD/ADRD and a greater risk of AD/ADRD. Screening for financial hardship in AD/ADRD is key for addressing the needs of patients and caregivers but critical barriers include a lack of suitable screening measures. Current measures are very general and meant for people without chronic medical conditions or are specific to other diseases. To fill this gap, this study will create a suite of measures that can screen for financial hardship in people with AD/ADRD and their families and caregivers. The measures will include a set to assess caregiver burden; a set to assess patient hardship as reported by the caregiver for patients who cannot report for themselves; and a set of patient-reported measures for patients that are able to report for themselves. To create these financial hardship screening measures, the project will conduct the following aims. Aim 1- Develop financial hardship screening measures for Alzheimer's Disease and related dementias: Using interviews with both caregivers and people with AD/ADRD, key indicators of financial hardship that are unique to AD/ADRD and the point in the lifespan in which it occurs will be identified. The ways that social and caregiver network size affect financial hardship will also be explored. Using the interviews and previous measures, preliminary measures will be created and will be reviewed by experts and a patient and caregiver advisory board. Aim 2- Create item response theory-based screening measures for financial hardship measures in Alzheimer's Disease and related dementias: Large samples of people with AD/ADRD (n=1000) and caregivers (n=1000) will be surveyed and item response theory will be used to evaluate and revise the measures and create scoring algorithms. A sample of additional caregivers matched to primary caregivers (n=400) will also be recruited to evaluate interrater reliability of the measures. Aim 3- Evaluate the financial hardship measures across patient and caregiver populations: Using the sample from Aim 2 and item response theory, we will evaluate the financial hardship screening measures across the following groups to ensure they are unbiased and reflect true differences: race/ethnicity; patient comorbidities; stage of AD/ADRD; caregiver relationship; social network size; number of caregivers; financial support provided; and caregiver's own health status (disability, comorbidities). The resulting measures will improve identification of financial hardship in AD/ADRD.
Conditions: Financial Hardship; Alzheimer's Disease (AD); Alzheimer's Disease and Related Dementia (ADRD)
Eligibility criteria
Copied from the official record. The study team makes the final decision at screening.
Show full criteria
Inclusion Criteria
- Adults aged 18 years or older
- One of the following:
- Clinical diagnosis of Alzheimer's disease or related dementia
- Being a caregiver to individuals with clinical diagnosis of Alzheimer's disease or related dementia
- Able to read and speak English or Spanish
- Able to provide informed consent
- Residing in the United States
Exclusion Criteria
- Cognitive impairment precluding informed consent
Recruiting US locations
Fred Hutchinson Cancer Center
Seattle, WA 98109
Site contact: Salene MW Jones, PhD, MA · 206-667-6976 · smjones3@fredhutch.org
Study contacts (from the official record)
- Diana K Lowry, MPH · 206-667-7372 · dlowry@fredhutch.org
- Salene Jones, PhD, MA · 206-667-6976 · smjones3@fredhutch.org
Similar studies in Washington
All neurology studies in Washington →- RecruitingPhase 3
Study to Evaluate Safety, Efficacy and Pharmacokinetics (PK) of a Modified Regimen of Ublituximab
TG Therapeutics, Inc.
- Location
- Kirkland, WA + 35 other US sites
- Eligibility basics
- Ages 18–65
- RecruitingPhase 2/Phase 3
A Study to Determine if BHV-8000 is Effective, Safe and Tolerable as a Treatment for Adults Living With Early Parkinson's Disease
Biohaven Therapeutics Ltd.
- Location
- Bellevue, WA + 24 other US sites
- Eligibility basics
- Ages 40–80
- RecruitingPhase 2
Study of AGN-151607-DP to Assess Adverse Events and Change in Disease Activity in Adult Participants With Upper Limb Essential Tremor
AbbVie
- Location
- Spokane, WA + 17 other US sites
- Eligibility basics
- Ages 18–85
- RecruitingPhase 1
Study of KITE-363 in Participants With Autoimmune Neurologic Diseases That Did Not Respond to Usual Treatment
Kite, A Gilead Company
- Location
- Seattle, WA + 4 other US sites
- Eligibility basics
- Ages 18–75